Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 1, 2017 – The FDA announced the approval of Ogivri (trastuzumab-dkst), Mylan and Biocon’s biosimilar to Genentech’s Herceptin® (trastuzumab).
Download PDF
Return to publications
